These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 22996365)
1. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells. Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365 [TBL] [Abstract][Full Text] [Related]
2. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349 [TBL] [Abstract][Full Text] [Related]
3. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372 [TBL] [Abstract][Full Text] [Related]
4. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate. Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685 [TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study. Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399 [TBL] [Abstract][Full Text] [Related]
6. In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study. Pressey JG; Adams J; Harkins L; Kelly D; You Z; Lamb LS Medicine (Baltimore); 2016 Sep; 95(39):e4909. PubMed ID: 27684826 [TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach. Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791 [TBL] [Abstract][Full Text] [Related]
8. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer. Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555 [TBL] [Abstract][Full Text] [Related]
9. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses. Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630 [TBL] [Abstract][Full Text] [Related]
10. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312 [TBL] [Abstract][Full Text] [Related]
11. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. Todaro M; D'Asaro M; Caccamo N; Iovino F; Francipane MG; Meraviglia S; Orlando V; La Mendola C; Gulotta G; Salerno A; Dieli F; Stassi G J Immunol; 2009 Jun; 182(11):7287-96. PubMed ID: 19454726 [TBL] [Abstract][Full Text] [Related]
12. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy. Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998 [TBL] [Abstract][Full Text] [Related]
13. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo. Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057 [TBL] [Abstract][Full Text] [Related]
14. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120 [TBL] [Abstract][Full Text] [Related]
15. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953 [TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid. Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667 [TBL] [Abstract][Full Text] [Related]
17. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate. Li Z; Peng H; Xu Q; Ye Z J Orthop Res; 2012 May; 30(5):824-30. PubMed ID: 22025284 [TBL] [Abstract][Full Text] [Related]
18. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain. Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461 [TBL] [Abstract][Full Text] [Related]
19. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma]. Li Z; Tang J; Sun L; Ye Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710 [TBL] [Abstract][Full Text] [Related]
20. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement. Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]